HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CROHN’S DISEASE: POSITION PAPER FROM THE TRANSPLANTATION COMMITTEE OF THE BRAZILIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASES (GEDIIB)

• Autor(a) principal: RUIZ,Milton Artur
• Data de Publicação: 2022
• Outros Autores: PARRA,Rogério Serafim, ZABOT,Gilmara Pandolfo, ANDRADE,Adriana Ribas, PIRON-RUIZ,Lilian, FONSECA-HIAL,Ana Marcela Rojas, MARTIN,Eloisa Moreira, PINHO,Tainara Souza, QUADROS,Luiz Gustavo de, KAISER JUNIOR,Roberto Luiz, PARENTE,José Miguel Luz
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de gastroenterologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032022000400462
• topic: Crohn’s disease; inflammatory bowel diseases; stem cell transplantation; hematopoietic stem cell transplantation

ABSTRACT Crohn’s disease (CD) is a relapse-remitting inflammatory bowel disease that can affect any part of the digestive system. This heterogeneous disease has multiple factors that contribute to an abnormal immune response to intestinal microorganisms. Treatment is based on the use of anti-inflammatories, corticosteroids, immunosuppressants and biologic biologic agents either alone or in combination. Surgical treatment is usual and, ten years after diagnosis, more than 80% of patients report having undergone surgical procedures related to the disease. Unfortunately, none of the treatments described offer a cure, and many cases become refractory or without therapeutic options. In this scenario, hematopoietic stem cell transplantation has been suggested because clinical remission was obtained in patients who had CD associated with malignant hematological diseases and an alternative since the first reports in 2010. In this report, the Transplantation Committee of the Brazilian Group for the Study of Inflammatory Bowel Diseases reviews the history and results of the procedure in patients with CD, detailing and discussing the various relevant points that permeate hematopoietic stem cell transplantation and cell therapy in this disease.